Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

odanacatib

- PMLiVE

First WHO Global Clinical Trial Forum develops joint vision to improve clinical research

Experts in areas including cancer, AMR and neurological diseases participated

- PMLiVE

Merck shares positive phase 3 results for investigational pneumococcal vaccine in adults

V116 is designed to address the strains responsible for adult pneumococcal disease

The problem with clinical trials (and how virtual insight-gathering can help)

While still the gold standard of research, clinical trials are often riddled with issues that limit their applicability to broader populations or delay market access.

Impetus Digital

- PMLiVE

UK government and NIHR accelerate plans to improve clinical research delivery

The government has created a focused plan for action to transform UK clinical research

- PMLiVE

Innovative Trials at the 2023 Lloyds Bank British Business Excellence Awards

Innovative Trials achievements recognized at the Lloyds Bank British Business Excellence Awards

Innovative Trials

- PMLiVE

ABPI report shows improvement in UK industry clinical trial performance

The data showed a 15% increase in annual recruitment to UK industry clinical trials

- PMLiVE

Novartis gains global rights to Legend’s CAR-T cell therapies in deal worth over $1bn

Novartis can apply its T-Charge platform to the manufacturing process of the therapies

- PMLiVE

Merck’s Keytruda combination receives CHMP recommendation for biliary tract cancer

Approximately 211,000 people are diagnosed with the disease globally each year

- PMLiVE

Merck shares positive results for adjuvant Keytruda in phase 3 kidney cancer trial

Renal cell carcinoma accounts for approximately 90% of all kidney cancer diagnoses

- PMLiVE

Merck’s Keytruda combination granted FDA approval for biliary tract cancer

Approximately 20,000 people are diagnosed with the disease each year in the US

- PMLiVE

Amgen’s Wezlana receives FDA approval to treat multiple inflammatory diseases

Wezlana is approved as a biosimilar referencing Janssen Pharmaceuticals’ Stelara

- PMLiVE

Novartis’ Cosentyx receives FDA approval for hidradenitis suppurativa

The decision makes Cosentyx the first biologic treatment approved for HS in nearly a decade

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links